<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728295</url>
  </required_header>
  <id_info>
    <org_study_id>PD014</org_study_id>
    <nct_id>NCT04728295</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)</brief_title>
  <official_title>Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the&#xD;
      Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's&#xD;
      Disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, open label, single-arm, multi-center clinical trial to establish&#xD;
      the safety and effectiveness of bilateral PTTractotomy for the treatment of motor&#xD;
      complications in patients with bilateral idiopathic Parkinson's Disease. A maximum of 50&#xD;
      subjects will be treated at up to 8 sites.&#xD;
&#xD;
      Subjects will undergo an Exablate index procedure targeting the PTT and will be seen at&#xD;
      1-week,1-, 3-, and 6- months post treatment. At the 6-month visit, subjects will be evaluated&#xD;
      for an Exablate procedure on the other side.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a bilateral study. Subjects will be treated on one side of the brain and will be allowed to receive treatment on the other side if eligible.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III OFF Medication</measure>
    <time_frame>Up to Month 3 post Bilateral Treatment</time_frame>
    <description>OFF-medication, Upper + Lower Extremity motor score from the MDS-UPDRS Part III comparing Month 3 post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part II</measure>
    <time_frame>Up to Month 12 post Bilateral Treatment</time_frame>
    <description>MDS-UPDRS Part II - Activities of Daily living comparing all Bilateral scheduled visits to Baseline. Lower score on the scale means a better outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III OFF Medication</measure>
    <time_frame>Up to Month 12 post Bilateral Treatment</time_frame>
    <description>OFF-medication, Upper + Lower Extremity motor score from the MDS-UPDRS Part III comparing all visits post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part IV</measure>
    <time_frame>Up to Month 12 post Bilateral Treatment</time_frame>
    <description>MDS-UPDRS Part IV at all Bilateral visits comparing all visits post Bilateral treatment to Baseline. Lower score on the scale means a better outcome.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Exablate Pallidothalamic Tractotomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exablate treatment for Advanced Idiopathic Parkinson's Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Exablate 4000</intervention_name>
    <description>Exablate Pallidothalamic Tractotomy</description>
    <arm_group_label>Exablate Pallidothalamic Tractotomy</arm_group_label>
    <other_name>MRgFUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, age 30 years and older, desiring bilateral treatment option with second&#xD;
             side staged at 6 months.&#xD;
&#xD;
          2. Subject is able and willing to give informed consent and able to attend all study&#xD;
             visits&#xD;
&#xD;
          3. Subject with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a&#xD;
             movement disorder neurologist at the site.&#xD;
&#xD;
          4. Subject has Levodopa responsive as defined by at least a 30% reduction in MDSUPDRS&#xD;
             motor subscale in the ON vs OFF medication state.&#xD;
&#xD;
          5. Subject has MDS-UPDRS score of 30 or greater in the meds OFF condition.&#xD;
&#xD;
          6. Motor complications of PD on optimum medical treatment characterized dyskinesia&#xD;
             (MDS-UPDRS item 4.2 score of 2 or greater in the meds ON condition) OR Motor&#xD;
             fluctuations (MDS-UPDRS item 4.4 score of 2 or greater in the meds ON condition)&#xD;
&#xD;
          7. Subject is on a stable dose of all PD medications for 30 days prior to screening visit&#xD;
             PD assessments as determined by medical records&#xD;
&#xD;
          8. Subject is able to communicate sensations during the Exablate procedure.&#xD;
&#xD;
          9. Subject's Pallido-thalamic region can be targeted by the Exablate device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a score of 3 or greater on the PULL test.&#xD;
&#xD;
          2. Subject with severe premorbid risks as specified in the MDS-UPDRS Part II subsection&#xD;
             motor aspects of experiences of daily living scores: 3 or 4 on question 2.1 (speech)&#xD;
             OR 3 or 4 on question 2.3 (chewing and swallowing) OR 4 on question 2.2 (saliva and&#xD;
             drooling).&#xD;
&#xD;
          3. Subject where there is suspicion that Parkinsonian symptoms are a side effect from&#xD;
             neuroleptic medications.&#xD;
&#xD;
          4. Subject with significant cognitive impairment as determined by the neuropsychologist.&#xD;
&#xD;
          5. Subject has other central neurodegenerative disease suspected on neurological&#xD;
             examination. These include: multisystem atrophy, progressive supranuclear palsy,&#xD;
             corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.&#xD;
&#xD;
          6. Subject with unstable psychiatric disease, defined as active uncontrolled depressive&#xD;
             symptoms, psychosis, delusions, hallucinations, or suicidal ideation&#xD;
&#xD;
          7. Women of childbearing potential who are pregnant or lactating&#xD;
&#xD;
          8. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse&#xD;
&#xD;
          9. Subject with unstable cardiac status or severe hypertension including:&#xD;
&#xD;
               -  Documented myocardial infarction within six months of enrollment&#xD;
&#xD;
               -  Unstable angina on medication&#xD;
&#xD;
               -  Unstable or worsening congestive heart failure&#xD;
&#xD;
               -  Left ventricular ejection fraction below the lower limit of normal&#xD;
&#xD;
               -  History of a hemodynamically unstable cardiac arrhythmia&#xD;
&#xD;
               -  Cardiac pacemaker&#xD;
&#xD;
               -  Diastolic BP &gt; 100 on medication&#xD;
&#xD;
         10. Subject with history of abnormal bleeding, hemorrhage, or coagulopathy including:&#xD;
&#xD;
               -  Subject with risk factors for intraoperative or postoperative bleeding as&#xD;
                  indicated by: platelet count less than 100,000 per cubic millimeter; a documented&#xD;
                  clinical coagulopathy; or INR coagulation studies exceeding the institution's&#xD;
                  laboratory standard.&#xD;
&#xD;
               -  History of intracranial hemorrhage, multiple strokes, or a stroke within past 6&#xD;
                  months&#xD;
&#xD;
               -  Subjects with intracranial aneurysms requiring treatment or arterial venous&#xD;
                  malformations (AVMs) requiring treatment&#xD;
&#xD;
         11. Subject is receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin)&#xD;
             therapy within one week of focused ultrasound procedure or drugs known to increase&#xD;
             risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.&#xD;
&#xD;
         12. Subject with severely impaired renal function with estimated glomerular filtration&#xD;
             rate &lt;30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or&#xD;
             who is on dialysis.&#xD;
&#xD;
         13. Subjects with a history of seizures within the past year.&#xD;
&#xD;
         14. Subject with an intracranial brain tumor&#xD;
&#xD;
         15. Subjects with life-threatening systemic disease that include and not limited to the&#xD;
             following will be excluded from the study participation: HIV, liver failure, blood&#xD;
             dyscrasias, etc.&#xD;
&#xD;
         16. Any illness that in the investigator's opinion preclude participation in this study.&#xD;
&#xD;
         17. Subject with standard contraindications for MR imaging such as implanted metallic&#xD;
             devices&#xD;
&#xD;
         18. Subject who had prior deep brain stimulation of the basal ganglia or thalamus.&#xD;
&#xD;
         19. Subjects who are unable to tolerate the required prolonged stationary supine position&#xD;
             during treatment.&#xD;
&#xD;
         20. Subjects who have an Overall Skull Density Ratio of less than 0.40 as calculated from&#xD;
             the screening CT.&#xD;
&#xD;
         21. Subject who is participating in another clinical investigation with an active&#xD;
             treatment arm in the last 30 days.&#xD;
&#xD;
         22. Subject who is unable to communicate with the investigator and staff. Additional&#xD;
             Exclusion Criteria for Staged Bilateral PTT procedure&#xD;
&#xD;
         23. Subject who had moderate to severe neurological event such as dysphagia, speech, gait&#xD;
             imbalance, cognitive impairment, and visual field deficit following index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaganjot Sooch</last_name>
    <phone>214-630-2000</phone>
    <email>gaganjots@insightec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bharati Sanjanwala</last_name>
      <phone>650-721-2830</phone>
      <email>bharatis@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Vivek Buch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Henry</last_name>
      <phone>410-328-0939</phone>
      <email>khenry@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Eisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Fishman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathryn Lapierre</last_name>
      <email>Cathryn.lapierre@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Alon Mogilner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Olovyannikov</last_name>
      <phone>212-746-7373</phone>
      <email>rao4005@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blagovest Nikolov</last_name>
      <phone>212-746-9882</phone>
      <email>Bln2001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Kaplitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harini Sarva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Bing Show Chwan Memorial Hospital</name>
      <address>
        <city>Lugang</city>
        <state>Changhua County</state>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Chieh Chang, MD</last_name>
      <email>changweichieh@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yen-Hui Yang</last_name>
      <phone>:+886-4-7813888</phone>
      <phone_ext>70379</phone_ext>
      <email>irene.yang71917@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exablate</keyword>
  <keyword>MRgFUS</keyword>
  <keyword>Pallidothalamic Tract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

